In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1835 News Items found
In the Lab
Stem cells induced to become cardiomyocytes
Stem Cell Research Probes Why a Breast Cancer Treatment Sometimes Damages the Heart

Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.
Q&A
MSK woman
The Benefits of a Metastatic Breast Cancer Support Group: An Interview with a Social Worker

Learn how a support group could help you if you’ve been diagnosed with metastatic breast cancer.
In the Lab
A micrograph image of breast cancer cells.
Research Reveals How Sleeping Cancer Cells Wake Up

MSK investigators are studying how dormant cancer cells can become reactivated after remaining hidden in the body for years.
In the Clinic
Image of DNA helix with sequence in the background
Genetic ‘Scars’ Provide Clues for Tailoring Cancer Treatment

For the first time, scientists have determined the extent of DNA repair deficiencies across cancer types. Learn what it means for patients.
Quiz
MSK medical oncologist Jasmeet Singh
How Much Do You Know about Breast Cancer Screening? Take Our Quiz

Take a short quiz to test your knowledge of breast cancer screening.
Memorial Sloan Kettering Is Designated as a Qualified Provider-Led Entity under the Protecting Access to Medicare Act

Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.
In the Clinic
A hand holding a thin optical fiber giving off a red light.
Light-Activated Drug Destroys Small Prostate Cancers with Fewer Side Effects

A novel treatment for prostate cancer involves a light-sensitive drug that destroys small tumors and the blood vessels that feed them.
m6A Enzymes Found to Be Central to the Development of AML

A team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and Weill-Cornell Medical College have identified, for the first time, a new molecular pathway that is required for acute myeloid leukemia (AML) development. This work could provide a rationale for targeting the RNA methylation program in myeloid leukemia.
Q&A
MSK pediatric neuropsychologist Stephen Sands
At Work: Child Psychologist Stephen Sands

Learn how child psychologist Stephen Sands supports pediatric patients at Memorial Sloan Kettering.
Science Byte
Petri dish with green mold on it
Insight into How Lungs Repel Infection Could Guide Therapies for Transplant Patients

Learn how immune cells in the lungs trigger invasive fungal cells to self-destruct. The discovery could produce therapies to prevent infection in cancer patients.